ArticleOrphanet journal of rare diseases2017
Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: a decade's experience.
Article in Orphanet journal of rare diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Immunodeficiency-Associated Childhood Interstitial Lung Diseases: Data from the Türkiye chILD Registry.Balkan medical journal · 2026Article
- Engraftment of wild-type alveolar type II epithelial cells in surfactant protein C deficient mice.NPJ Regenerative medicine · 2026Article
- Persistent tachypnoea of infancy and neuroendocrine cell hyperplasia of infancy: from systematic review to future directions.ERJ open research · 2025Article
- Genetic Testing Utilization in the U.S. Registry for Childhood Interstitial and Diffuse Lung Diseases.Pediatric pulmonology · 2025Observational
- An update on diagnosis and treatments of childhood interstitial lung diseases.Breathe (Sheffield, England) · 2025Review
- The US national registry for childhood interstitial and diffuse lung disease: Report of study design and initial enrollment cohort.Pediatric pulmonology · 2024Observational
- Innovations in Childhood Interstitial and Diffuse Lung Disease.Clinics in chest medicine · 2024Review
- Clinical scope and healthcare utilization in childhood interstitial lung disease at a tertiary center.Pediatric pulmonology · 2024Article
- Diagnostic workup of childhood interstitial lung disease.European respiratory review : an official journal of the European Respiratory Society · 2023Review
- An Infant Presenting with Interstitial Lung Disease Diagnosed Later as Hunter Syndrome: A Case Report.The American journal of case reports · 2022Article
- The role of exome sequencing in childhood interstitial or diffuse lung disease.Orphanet journal of rare diseases · 2022Article
- Pediatric hypersensitivity pneumonitis: literature update and proposal of a diagnostic algorithm.Italian journal of pediatrics · 2022Review
- Etiologic Classification of Diffuse Parenchymal (Interstitial) Lung Diseases.Journal of clinical medicine · 2022Article
- Article
- Genomic testing for children with interstitial and diffuse lung disease (chILD): parent satisfaction, understanding and health-related quality of life.BMJ open respiratory research · 2022Article
- Cellular Therapy for the Treatment of Paediatric Respiratory Disease.International journal of molecular sciences · 2021Review
- Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease.ERJ open research · 2021Article
- Spectrum of childhood interstitial and diffuse lung diseases at a tertiary hospital in Egypt.ERJ open research · 2021Article
- Children's Interstitial and Diffuse Lung Diseases (ChILD) in 2020.Children (Basel, Switzerland) · 2020Review
- Nebulized step-down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study.Experimental and therapeutic medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundChildhood interstitial lung disease (chILD) represents a rare heterogeneous group of respiratory disorders. In the absence of randomized controlled clinical trials, global collaborations have utilized case series with an aim to standardising approaches to diagnosis and management. Australasian data are lacking. The aim of this study was to calculate prevalence and report the experience of chILD in Australasia over a decade.
methodsPaediatric pulmonologists in Australia and New Zealand involved in the care of patients aged 0-18 years with chILD completed a questionnaire on demographics, clinical features and outcomes, over a 10 year period. These data, together with data from the 2 reference genetics laboratories, were used to calculate prevalence.
resultsOne hundred fifteen cases were identified equating to a period prevalence (range) of 1.5 (0.8-2.1) cases/million for children aged 0-18years. Clinical data were provided on 106 patients: the <2 year group comprised 66 children, median age (range) 0.50 years (0.01-1.92); the ≥2 year group comprised 40 children, median age 8.2 years (2.0-18.0). Management approach was heterogeneous. Overall, 79% of patients had a good clinical outcome. Mortality rate was 7% in the study population.
conclusionchILD is rare in Australasia. This study demonstrates variation in the investigations and management of chILD cases across Australasia, however the general outcome is favorable. Further international collaboration will help finesse the understanding of these disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.